These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33544369)

  • 1. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization.
    Schwarting A; Friedel H; Garal-Pantaler E; Pignot M; Wang X; Nab H; Desta B; Hammond ER
    Rheumatol Ther; 2021 Mar; 8(1):375-393. PubMed ID: 33544369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany.
    Schultze M; Garal-Pantaler E; Pignot M; Levy RA; Carnarius H; Schneider M; Gairy K
    BMC Rheumatol; 2024 May; 8(1):18. PubMed ID: 38755673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States.
    Murimi-Worstell IB; Lin DH; Kan H; Tierce J; Wang X; Nab H; Desta B; Alexander GC; Hammond ER
    J Rheumatol; 2021 Mar; 48(3):385-393. PubMed ID: 32611669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Resource Utilization and Associated Costs in Patients With Systemic Lupus Erythematosus Diagnosed With Lupus Nephritis.
    Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM; Von Feldt J
    Cureus; 2023 Apr; 15(4):e37839. PubMed ID: 37214060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
    He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
    Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study.
    McCormick N; Marra CA; Sadatsafavi M; Aviña-Zubieta JA
    Lupus; 2018 Jul; 27(8):1247-1258. PubMed ID: 29665755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
    Kariburyo F; Xie L; Sah J; Li N; Lofland JH
    J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
    [No Abstract]   [Full Text] [Related]  

  • 8. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study.
    Tanaka Y; Mizukami A; Kobayashi A; Ito C; Matsuki T
    Int J Rheum Dis; 2018 Aug; 21(8):1609-1618. PubMed ID: 30146745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study.
    Miyazaki C; Sruamsiri R; Mahlich J; Jung W
    J Med Econ; 2020 Jul; 23(7):786-799. PubMed ID: 32149541
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims.
    Garris C; Shah M; Farrelly E
    Cost Eff Resour Alloc; 2015; 13():9. PubMed ID: 26019689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.
    Clarke AE; Yazdany J; Kabadi SM; Durden E; Winer I; Griffing K; Costenbader KH
    Semin Arthritis Rheum; 2020 Aug; 50(4):759-768. PubMed ID: 32531505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
    Jiang M; Near AM; Desta B; Wang X; Hammond ER
    Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare utilization and costs of systemic lupus erythematosus in Medicaid.
    Kan HJ; Song X; Johnson BH; Bechtel B; O'Sullivan D; Molta CT
    Biomed Res Int; 2013; 2013():808391. PubMed ID: 23484162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-of-illness changes before and after the diagnosis of systemic lupus erythematosus: a nationwide, population-based observational study in Korea.
    Kim H; Jang EJ; Cho SK; Han JY; Jeon Y; Jung SY; Sung YK
    Rheumatology (Oxford); 2023 Dec; ():. PubMed ID: 38070482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany.
    Ding B; Pignot M; Garal-Pantaler E; Villinger B; Schefzyk S; Desta B; Stirnadel-Farrant HA; Schwarting A
    Rheumatol Ther; 2024 Apr; 11(2):285-299. PubMed ID: 38252212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare Resource Use and Costs Associated with Organ Damage in Newly Diagnosed Adults with Systemic Lupus Erythematosus in the UK.
    Stirnadel-Farrant HA; Golam SM; Naisbett-Groet B; Gibson D; Langham J; Langham S; Samnaliev M
    Rheumatol Ther; 2023 Oct; 10(5):1183-1197. PubMed ID: 37400683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease.
    Karve S; Candrilli S; Kappelman MD; Tolleson-Rinehart S; Tennis P; Andrews E
    J Pediatr; 2012 Oct; 161(4):662-670.e2. PubMed ID: 22578787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.